Mark D Lindner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6533185/publications.pdf

Version: 2024-02-01

201674 189892 2,568 55 27 50 citations h-index g-index papers 61 61 61 2133 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	An experimental test of the effects of redacting grant applicant identifiers on peer review outcomes. ELife, 2021, 10, .	6.0	16
2	NIH peer review: Criterion scores completely account for racial disparities in overall impact scores. Science Advances, 2020, 6, eaaz4868.	10.3	63
3	Scientific productivity: An exploratory study of metrics and incentives. PLoS ONE, 2018, 13, e0195321.	2.5	31
4	NIH Peer Review. American Journal of Evaluation, 2016, 37, 238-249.	2.1	20
5	Examining the Predictive Validity of NIH Peer Review Scores. PLoS ONE, 2015, 10, e0126938.	2.5	20
6	Overview of Mouse Models for Psychiatric and Neurologic Disorders. , 2012, , 738-751.		0
7	Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity. Behavioural Pharmacology, 2009, 20, 237-251.	1.7	57
8	Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease., 2008,, 93-157.		10
9	Clinical attrition due to biased preclinical assessments of potential efficacy., 2007, 115, 148-175.		50
10	Soluble $\hat{Al^2}$ and cognitive function in aged F-344 rats and Tg2576 mice. Behavioural Brain Research, 2006, 173, 62-75.	2.2	17
11	Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy Experimental and Clinical Psychopharmacology, 2006, 14, 42-51.	1.8	16
12	The Pharmacology of DMP696 and DMP904, Non-Peptidergic CRF1 Receptor Antagonists. CNS Neuroscience & Therapeutics, 2006, 11, 21-52.	4.0	53
13	Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology, 2006, 188, 629-640.	3.1	55
14	Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests. Psychopharmacology, 2005, 178, 410-419.	3.1	20
15	Did Experimenter Bias Conceal the Efficacy of Spinal Opioids in Previous Studies with the Spinal Nerve Ligation Model of Neuropathic Pain?. Anesthesiology, 2004, 100, 765-767.	2.5	22
16	Analgesic effects of adrenal chromaffin allografts: Contingent on special procedures or due to experimenter bias?. Journal of Pain, 2003, 4, 64-73.	1.4	14
17	An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 682-691.	2.5	98
18	Long-Lasting Functional Disabilities in Middle-Aged Rats with Small Cerebral Infarcts. Journal of Neuroscience, 2003, 23, 10913-10922.	3.6	111

#	Article	IF	Citations
19	Conditional analgesia from spinally transplanted adrenal chromaffin cells. Pain, 2002, 95, 192-194.	4.2	О
20	No detectable analgesic effects in the formalin test even with one million bovine adrenal chromaffin cells. Pain, 2002, 99, 263-271.	4.2	12
21	The analgesic potential of intraventricular polymer-encapsulated adrenal chromaffin cells in a rodent model of chronic neuropathic pain Experimental and Clinical Psychopharmacology, 2000, 8, 524-538.	1.8	8
22	Mammalian-Cell-Produced Neurturin (NTN) Is More Potent Than Purified Escherichia coli-Produced NTN. Experimental Neurology, 2000, 162, 189-193.	4.1	14
23	Intrathecal Polymer-Encapsulated Bovine Adrenal Chromaffin Cells Fail to Produce Analgesic Effects in the Hotplate and Formalin Test. Experimental Neurology, 2000, 165, 370-383.	4.1	14
24	Numerous adrenal chromaffin cell preparations fail to produce analgesic effects in the formalin test or in tests of acute pain even with nicotine stimulation. Pain, 2000, 88, 177-188.	4.2	20
25	Development of Behavioral Outcome Measures for Preclinical Parkinson's Research. , 2000, , 153-169.		2
26	The analgesic potential of intraventricular polymer-encapsulated adrenal chromaffin cells in a rodent model of chronic neuropathic pain Experimental and Clinical Psychopharmacology, 2000, 8, 524-538.	1.8	3
27	Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behavioural Brain Research, 1999, 102, 1-16.	2.2	91
28	Differential in Vivo Effects of Neurturin and Glial Cell-Line-Derived Neurotrophic Factor. Experimental Neurology, 1999, 160, 235-243.	4.1	45
29	Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain Experimental and Clinical Psychopharmacology, 1999, 7, 187-197.	1.8	26
30	Therapeutic Potential of a Polymer-Encapsulated ?-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson's Disease. Cell Transplantation, 1998, 7, 165-174.	2.5	30
31	Dissociable Long-Term Cognitive Deficits after Frontal versus Sensorimotor Cortical Contusions. Journal of Neurotrauma, 1998, 15, 199-216.	3.4	109
32	Treatment of Central Nervous System Diseases with Polymer-Encapsulated Xenogeneic Cells. , 1998, , 253-286.		0
33	Intraventricular encapsulated calf adrenal chromaffin cells: viable for at least 500 days in vivo without detectable adverse effects on behavioral/cognitive function or host immune sensitization in rats. Restorative Neurology and Neuroscience, 1997, 11, 21-35.	0.7	9
34	Cellular Delivery of Human Cntf Prevents Motor and Cognitive Dysfunction in a Rodent Model of Huntington's Disease. Cell Transplantation, 1997, 6, 249-266.	2.5	67
35	Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplantation, 1997, 6, 249-266.	2.5	68
36	Somatic Delivery of Catecholamines in the Striatum Attenuate Parkinsonian Symptoms and Widen the Therapeutic Window of Oral Sinemet in Rats. Experimental Neurology, 1997, 145, 130-140.	4.1	19

#	Article	IF	CITATIONS
37	Reliability, Distribution, and Validity of Age-Related Cognitive Deficits in the Morris Water Maze. Neurobiology of Learning and Memory, 1997, 68, 203-220.	1.9	162
38	Blind rats are not profoundly impaired in the reference memory Morris water maze and cannot be clearly discriminated from rats with cognitive deficits in the cued platform task. Cognitive Brain Research, 1997, 5, 329-333.	3.0	80
39	Pain-Related Disability and Effects of Chronic Morphine in the Adjuvant-Induced Arthritis Model of Chronic Pain. Physiology and Behavior, 1997, 62, 199-205.	2.1	46
40	Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task. Behavioural Brain Research, 1997, 86, 25-40.	2.2	57
41	Continued presence of intrastriatal but not intraventricular polymer-encapsulated PC12 cells is required for alleviation of behavioral deficits in Parkinsonian rodents. Cell Transplantation, 1996, 5, 589-596.	2.5	22
42	Individual differences in the hotplate test and effects of habituation on sensitivity to morphine. Pain, 1996, 66, 265-270.	4.2	63
43	Polymer-Encapsulated Genetically Modified Cells Continue to Secrete Human Nerve Growth Factor for over One Year in Rat Ventricles: Behavioral and Anatomical Consequences. Experimental Neurology, 1996, 140, 126-138.	4.1	72
44	Validation of a rodent model of Parkinson's disease: Evidence of a therapeutic window for oral Sinemet. Brain Research Bulletin, 1996, 39, 367-372.	3.0	42
45	Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington's Disease. Journal of Neuroscience, 1996, 16, 5168-5181.	3.6	204
46	Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Research, 1996, 736, 99-110.	2.2	3
47	Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Experimental Neurology, 1995, 132, 62-76.	4.1	142
48	Increased Levels of Truncated Nerve Growth Factor Receptor in Urine of Mildly Demented Patients With Alzheimer's Disease. Archives of Neurology, 1993, 50, 1054-1058.	4.5	19
49	Short forms of the "reference-―and "working-memory―Morris water maze for assessing age-related deficits. Behavioral and Neural Biology, 1992, 58, 94-102.	2.2	72
50	Hypoxia produces cell death in the rat hippocampus in the presence of an A1 adenosine receptor antagonist: An anatomical and behavioral study. Neuroscience, 1992, 48, 807-812.	2.3	43
51	Effects of oral BMY 21502 on Morris water task performance in 16–18 month old F-344 rats. Psychopharmacology, 1992, 107, 485-488.	3.1	8
52	Relationship between performance in the morris water task, visual acuity, and thermoregulatory function in aged F-344 rats. Behavioural Brain Research, 1991, 45, 45-55.	2,2	73
53	Rescuing neurons from trans-synaptic degeneration after brain damage: Helpful, harmful, or neutral in recovery of function?. Canadian Journal of Psychology, 1990, 44, 276-292.	0.8	61
54	Aging and atropine effects on spatial navigation in the Morris water task Behavioral Neuroscience, 1988, 102, 621-634.	1.2	96

#	Article	IF	CITATIONS
55	The partial-reinforcement extinction effect in 4–5-day-old guinea pigs. Learning and Behavior, 1983, 11, 337-340.	3.4	1